1. Cancer Biology
  2. Structural Biology and Molecular Biophysics

Dynamics of human protein kinase Aurora A linked to drug selectivity

  1. Warintra Pitsawong
  2. Vanessa Buosi
  3. Renee Otten
  4. Roman V Agafonov
  5. Adelajda Zorba
  6. Nadja Kern
  7. Steffen Kutter
  8. Gunther Kern
  9. Ricardo AP Pádua
  10. Xavier Meniche
  11. Dorothee Kern  Is a corresponding author
  1. Howard Hughes Medical Institute, Brandeis University, United States
  2. University of Massachusetts Medical School, United States
https://doi.org/10.7554/eLife.36656
Share this article
Cite this article
  1. Warintra Pitsawong
  2. Vanessa Buosi
  3. Renee Otten
  4. Roman V Agafonov
  5. Adelajda Zorba
  6. Nadja Kern
  7. Steffen Kutter
  8. Gunther Kern
  9. Ricardo AP Pádua
  10. Xavier Meniche
  11. Dorothee Kern
(2018)
Dynamics of human protein kinase Aurora A linked to drug selectivity
eLife 7:e36656.
https://doi.org/10.7554/eLife.36656
  2. Download BibTeX
  3. Download .RIS

Abstract

Protein kinases are major drug targets, but the development of highly-selective inhibitors has been challenging due to the similarity of their active sites. The observation of distinct structural states of the fully-conserved Asp-Phe-Gly (DFG) loop has put the concept of conformational selection for the DFG-state at the center of kinase drug discovery. Recently, it was shown that Gleevec selectivity for the Tyr-kinases Abl was instead rooted in conformational changes after drug binding. Here, we investigate whether protein dynamics after binding is a more general paradigm for drug selectivity by characterizing the binding of several approved drugs to the Ser/Thr-kinase Aurora A. Using a combination of biophysical techniques, we propose a universal drug-binding mechanism, that rationalizes selectivity, affinity and long on-target residence time for kinase inhibitors. These new concepts, where protein dynamics in the drug-bound state plays the crucial role, can be applied to inhibitor design of targets outside the kinome.

Data availability

Diffraction data have been deposited in PDB under the accession codes 6CPE, 6CPF, 6CPG.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Warintra Pitsawong

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5438-1783

  2. Vanessa Buosi

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Renee Otten

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7342-6131

  4. Roman V Agafonov

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Adelajda Zorba

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4452-8419

  6. Nadja Kern

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Steffen Kutter

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Gunther Kern

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Ricardo AP Pádua

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Xavier Meniche

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Dorothee Kern

    Department of Biochemistry, Howard Hughes Medical Institute, Brandeis University, Waltham, United States
    For correspondence
    dkern@brandeis.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7631-8328

Funding

Howard Hughes Medical Institute

  • Dorothee Kern

National Institutes of Health (GM100966-01)

  • Dorothee Kern

U.S. Department of Energy (DE-FG02-05ER15699)

  • Dorothee Kern

Damon Runyon Cancer Research Foundation (DRG-2114-12)

  • Renee Otten

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Philip A Cole, Harvard Medical School, United States

Version history

  1. Received: March 14, 2018
  2. Accepted: June 12, 2018
  3. Accepted Manuscript published: June 14, 2018 (version 1)
  4. Version of Record published: July 20, 2018 (version 2)

Copyright

© 2018, Pitsawong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,465
    views
  • 780
    downloads
  • 39
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Warintra Pitsawong
  2. Vanessa Buosi
  3. Renee Otten
  4. Roman V Agafonov
  5. Adelajda Zorba
  6. Nadja Kern
  7. Steffen Kutter
  8. Gunther Kern
  9. Ricardo AP Pádua
  10. Xavier Meniche
  11. Dorothee Kern
(2018)
Dynamics of human protein kinase Aurora A linked to drug selectivity
eLife 7:e36656.
https://doi.org/10.7554/eLife.36656

Share this article

https://doi.org/10.7554/eLife.36656

Categories and tags

Research organism

Further reading

    1. Cancer Biology

    Netrin signaling mediates survival of dormant epithelial ovarian cancer cells

    Pirunthan Perampalam, James I MacDonald ... Frederick A Dick
    Research Article

    Dormancy in cancer is a clinical state in which residual disease remains undetectable for a prolonged duration. At a cellular level, rare cancer cells cease proliferation and survive chemotherapy and disseminate disease. We created a suspension culture model of high-grade serous ovarian cancer (HGSOC) dormancy and devised a novel CRISPR screening approach to identify survival genes in this context. In combination with RNA-seq, we discovered the Netrin signaling pathway as critical to dormant HGSOC cell survival. We demonstrate that Netrin-1, –3, and its receptors are essential for low level ERK activation to promote survival, and that Netrin activation of ERK is unable to induce proliferation. Deletion of all UNC5 family receptors blocks Netrin signaling in HGSOC cells and compromises viability during the dormancy step of dissemination in xenograft assays. Furthermore, we demonstrate that Netrin-1 and –3 overexpression in HGSOC correlates with poor outcome. Specifically, our experiments reveal that Netrin overexpression elevates cell survival in dormant culture conditions and contributes to greater spread of disease in a xenograft model of abdominal dissemination. This study highlights Netrin signaling as a key mediator HGSOC cancer cell dormancy and metastasis.

    1. Cancer Biology
    2. Cell Biology

    Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma

    Camille Dantzer, Justine Vaché ... Violaine Moreau
    Research Article

    Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which oncogenic ß-catenin affects immune surveillance remain unclear. Herein, we highlighted the involvement of ß-catenin in the regulation of the exosomal pathway and, by extension, in immune/cancer cell communication in hepatocellular carcinoma (HCC). We showed that mutated ß-catenin represses expression of SDC4 and RAB27A, two main actors in exosome biogenesis, in both liver cancer cell lines and HCC patient samples. Using nanoparticle tracking analysis and live-cell imaging, we further demonstrated that activated ß-catenin represses exosome release. Then, we demonstrated in 3D spheroid models that activation of β-catenin promotes a decrease in immune cell infiltration through a defect in exosome secretion. Taken together, our results provide the first evidence that oncogenic ß-catenin plays a key role in exosome biogenesis. Our study gives new insight into the impact of ß-catenin mutations on tumor microenvironment remodeling, which could lead to the development of new strategies to enhance immunotherapeutic response.

    1. Cancer Biology

    RBM7 deficiency promotes breast cancer metastasis by coordinating MFGE8 splicing switch and NF-kB pathway

    Fang Huang, Zhenwei Dai ... Yang Wang
    Research Article

    Aberrant alternative splicing is well-known to be closely associated with tumorigenesis of various cancers. However, the intricate mechanisms underlying breast cancer metastasis driven by deregulated splicing events remain largely unexplored. Here, we unveiled that RBM7 is decreased in lymph node and distant organ metastases of breast cancer as compared to primary lesions and low expression of RBM7 is correlated with the reduced disease-free survival of breast cancer patients. Breast cancer cells with RBM7 depletion exhibited an increased potential for lung metastasis compared to scramble control cells. The absence of RBM7 stimulated breast cancer cell migration, invasion, and angiogenesis. Mechanistically, RBM7 controlled the splicing switch of MFGE8, favoring the production of the predominant isoform of MFGE8, MFGE8-L. This resulted in the attenuation of STAT1 phosphorylation and alterations in cell adhesion molecules. MFGE8-L exerted an inhibitory effect on the migratory and invasive capability of breast cancer cells, while the truncated isoform MFGE8-S, which lack the second F5/8 type C domain had the opposite effect. In addition, RBM7 negatively regulates the NF-κB cascade and an NF-κB inhibitor could obstruct the increase in HUVEC tube formation caused by RBM7 silencing. Clinically, we noticed a positive correlation between RBM7 expression and MFGE8 exon7 inclusion in breast cancer tissues, providing new mechanistic insights for molecular-targeted therapy in combating breast cancer.